← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	926	-19	-2%	$21.6B
2	2 Charles River Laboratories CRL $14.4B	258	-3	-1%	$2.93B
3	3 DELISTED bluebird bio BLUE	192	-43	-18%	$3.13B
4	4 DELISTED CATALENT, INC. CTLT	176	+27	+18%	$3.04B
5	5 Precigen PGEN $2.64B	173	0	0%	$3.23B
6	6 Ultragenyx Pharmaceutical RARE $1.47B	162	+11	+7%	$3.41B
7	7 PTC Therapeutics PTCT $4.98B	157	+2	+1%	$884M
8	8 Sarepta Therapeutics SRPT $1.78B	149	+19	+15%	$892M
9	ISEE 9 DELISTED IVERIC bio, Inc. Common Stock ISEE	144	+5	+4%	$1.29B
10	10 DELISTED SANGAMO THERAPEUTICS INC SGMO	141	-15	-10%	$297M
11	11 DELISTED Adverum Biotechnologies ADVM	92	-4	-4%	$144M
12	12 Atara Biotherapeutics ATRA $96M	91	+17	+23%	$614M
13	BLCM 13 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	83	+2	+2%	$230M
14	14 Lineage Cell Therapeutics LCTX $232M	74	-6	-8%	$98.6M
15	SIOX 15 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	71	+19	+37%	$1.29B
16	16 uniQure QURE $1.45B	62	+9	+17%	$162M
17	AGTC 17 DELISTED Applied Genetic Technologies Corporation AGTC	60	-3	-5%	$121M
18	18 Rocket Pharmaceuticals RCKT $243M	53	+34	+179%	$175M
19	19 Regenxbio RGNX $454M	48	+48	–	$310M
20	ATHX 20 DELISTED Athersys, Inc. Common Stock ATHX	46	+5	+12%	$8.16M
21	21 Fate Therapeutics FATE $232M	44	+5	+13%	$97.8M
22	22 Abeona Therapeutics ABEO $249M	43	+1	+2%	$30.1M
23	23 Cellectis CLLS $113M	43	+3	+8%	$181M
24	ADAP 24 DELISTED Adaptimmune Therapeutics ADAP	41	-4	-9%	$181M
25	25 Fortress Biotech FBIO $63.4M	39	-2	-5%	$18.6M